REDWOOD CITY, Calif., Feb. 22 /PRNewswire/ -- Codexis, Inc., a privately held biosciences company, today announced it has acquired Germany's Julich Fine Chemicals GmbH (JFC), a leading supplier of specialty enzymes (biocatalysts) for organic synthesis and chiral building blocks to pharmaceutical and chemical companies worldwide. The acquisition is expected to make a positive cash contribution to Codexis in its first full year of operations. Additional financial terms were not disclosed.
JFC is one of Europe's leading providers of products and services for the biocatalytic production of chiral pharmaceutical intermediates. JFC will operate as an independent, wholly owned subsidiary of Codexis. Through its catalog, http://www.juelich-chemicals.de/shop.html , JFC offers a wide range of off-the-shelf specialty enzymes and chiral intermediates useful in pharmaceutical development. JFC will be an outlet for several of Codexis' proprietary enzymes, while Codexis will continue to focus on using its MolecularBreeding(TM) directed molecular evolution technology to provide proprietary, customized solutions directly to leading pharmaceutical companies worldwide.
"The acquisition of JFC is part of our strategic expansion into international markets, in particular Europe. We believe it will accelerate adoption of Codexis' biocatalytic approach to pharmaceutical process research and manufacturing, an area historically dominated by synthetic organic chemistry," said Alan Shaw, Ph.D., President and Chief Executive Officer of Codexis.
"Synergies between our companies can lead to accelerated revenue growth and greater market presence in Europe," Dr. Shaw added. "Codexis will continue to leverage its MolecularBreeding(TM) technology platform, streamlining Phase I and Phase II drug development and creating valuable intellectual property for our pharmaceutical partners."
"Our companies bring complementary expertise and market knowledge to the complex manufacturing challenges facing today's pharmaceutical companies," said Thomas Daussmann, Ph.D., Managing Director of JFC, who will join the Codexis leadership team. "We look forward to being part of Codexis as we address this rapidly growing worldwide market."
About the Company
Codexis is a privately held biosciences company applying proprietary protein and strain engineering technologies to create novel process development solutions for efficient, cost-effective and environmentally friendly pharmaceutical manufacturing. Application of the Codexis technology can also generate new intellectual property opportunities for pharmaceutical manufacturers, which may extend a product lifecycle. The company has more than 10 strategic alliances, including a major agreement with Pfizer, and more than 15 products and processes in development internally and at leading worldwide life sciences companies. Codexis, Inc. began operations as an independent company in 2002.
For more information about Codexis and its applications, please visit http://www.codexis.com/. Codexis is a trademark of Codexis, Inc.
Julich Fine Chemicals GmbH, a Codexis company, is focused on the production of chiral fine chemicals using biological systems such as isolated enzymes and microorganisms. Founded in 1999 as a spin-off from the Research Centre Julich in Germany, JFC offers specialty enzymes for organic chemistry, chiral intermediates and R&D services in biocatalysis. Specialty enzymes, including oxidoreductases, transferases, hydrolases (lipases, esterases, nitrilases) and lyases (oxynitrilases), are available for sale via JFC's catalog. The company also applies these enzymes for the production of chiral intermediates, including optically active alcohols, diols, hydroxy esters and amines. JFC's in-house production capabilities range from a few grams to the 100-kg scale, while quantities at the multi-ton scale are available through JFC's established manufacturing partners.
To learn more about JFC, including access to its catalog of products, please visit http://www.juelich-chemicals.com/ .
Sr. Vice President, Business Development
Kathy L. Nugent, Ph.D.
CONTACT: Tassos Gianakakos, Sr. Vice President, Business Development ofCodexis, Inc., +1-650-298-5423, or fax, +1-650-298-5449, email@example.com; or Kathy L. Nugent, Ph.D. of Burns McClellan,+1-212-213-0006, or firstname.lastname@example.org, for Codexis, Inc.